Trastuzumab: beside an established treatment under test

192 studies: an approved drug, surgery or radiation is what the study tests. Page 1 of 2. Open to participants first (40), then studies with results posted, then the rest; newest registration first within each.

• Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast CancerNot yet recruitingNCT07772245Phase 2Report a problem
• De-escalation Neoadjuvant Therapy for Intermediate Risk HER2-positive Early BreastNot yet recruitingNCT07748260Phase 3Report a problem
• Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast CancerRecruitingNCT07695259Phase 4Report a problem
• Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone MetastasesNot yet recruitingNCT07687225Not applicableReport a problem
• T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXdRecruitingNCT07683754Phase 3Report a problem
• Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.Not yet recruitingNCT07679269Phase 2Report a problem
• TAIC FOLFOX for Locally Advanced G/GEJARecruitingNCT07655024Phase 2Report a problem
• Elacestrant in Advanced Triple Positive Breast CancerRecruitingNCT07612215Phase 1/2Report a problem
• Effects of Instrument-Assisted Constant-Speed Injection Versus Manual Injection on Pain From Large-Volume Subcutaneous Injection of Pertuzumab and Trastuzumab in Breast Cancer: A Randomized, Self-Controlled StudyNot yet recruitingNCT07533526Not applicableReport a problem
• A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBCNot yet recruitingNCT07245797Phase 2Report a problem
• A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation ModelNot yet recruitingNCT07239271Phase 3Report a problem
• Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast CancerRecruitingNCT07220135Phase 2Report a problem
• CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast CancerNot yet recruitingNCT07213206Phase 3Report a problem
• Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast CancerRecruitingNCT07057427Phase 3Report a problem
• A Study of Surgery and Radiotherapy in People With Breast CancerRecruitingNCT07053085Phase 2Report a problem
• Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric AdenocarcinomaRecruitingNCT07000253Phase 2Report a problem
• A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)RecruitingNCT06992882Phase 3Report a problem
• Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric CancerRecruitingNCT06468280Phase 2Report a problem
• Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal CancerRecruitingNCT06245356Phase 2Report a problem
• Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast CancerRecruitingNCT06197581Not applicableReport a problem
• Metastasis-directed Therapy for Oligometastases of Breast CancerRecruitingNCT06135714Phase 3Report a problem
• Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ CancerRecruitingNCT06121700Phase 2Report a problem
• The Choice of Treatment Methods and Efficacy of LABCRecruitingNCT06080620Not applicableReport a problem
• EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast CancerRecruitingNCT05883852Phase 3Report a problem
• Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus PertuzumabRecruitingNCT05760612Phase 3Report a problem
• To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical StudyRecruitingNCT05656079Not applicableReport a problem
• A Study for the Adjuvant Treatment of Breast CancerRecruitingNCT05420467Phase 4Report a problem
• A Study for the Neoadjuvant Treatment of Breast CancerRecruitingNCT05420454Phase 4Report a problem
• Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast CancerRecruitingNCT05189067Phase 2/3Report a problem
• Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast CancerRecruitingNCT05159193Phase 3Report a problem
• Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast CancerRecruitingNCT04993014Phase 2Report a problem
• Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study)RecruitingNCT04858529Phase 3Report a problem
• TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)Not yet recruitingNCT04760431Phase 2Report a problem
• A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast CancerRecruitingNCT04547907Phase 3Report a problem
• Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast CancerNot yet recruitingNCT04337658Phase 3Report a problem
• Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial)Not yet recruitingNCT04301375Phase 2Report a problem
• Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy (VAB) and Sentinel Lymph Node Biopsy (SLNB)RecruitingNCT04293796Not applicableReport a problem
• Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric AdenocarcinomaRecruitingNCT04150640Phase 2Report a problem
• A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTientsRecruitingNCT03561740Phase 3Report a problem
• Neoadjuvant Chemotherapy Followed by Radiotherapy Alone in Patients With Breast CancerRecruitingNCT03213925Phase 2Report a problem
• A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerActive, not recruitingNCT05132582Phase 3Results postedReport a problem
• A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)Active, not recruitingNCT04721977Phase 2Results postedReport a problem
• A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal JunctionCompletedNCT04661150Phase 2Results postedReport a problem
• Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsActive, not recruitingNCT04579380Phase 2Results postedReport a problem
• Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal CancerCompletedNCT04499924Phase 2/3Results postedReport a problem
• Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal CancersActive, not recruitingNCT04430738Phase 2Results postedReport a problem
• Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast CancerTerminatedNCT04108858Phase 1/2Results postedReport a problem
• Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast CancerActive, not recruitingNCT04001829Phase 2Results postedReport a problem
• Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast CancerActive, not recruitingNCT03820141Phase 2Results postedReport a problem
• Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]Active, not recruitingNCT03747120Phase 2Results postedReport a problem
• Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)CompletedNCT03742986Phase 2Results postedReport a problem
• A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast CancerCompletedNCT03726879Phase 3Results postedReport a problem
• To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)CompletedNCT03644186Phase 2Results postedReport a problem
• Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)CompletedNCT03615326Phase 3Results postedReport a problem
• Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BCCompletedNCT03417544Phase 2Results postedReport a problem
• Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast CancerTerminatedNCT03329378Phase 2Results postedReport a problem
• Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast CancerTerminatedNCT03199885Phase 3Results postedReport a problem
• Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall DiseaseCompletedNCT03095352Phase 2Results postedReport a problem
• Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) CancerCompletedNCT02954536Phase 2Results postedReport a problem
• Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast CancerActive, not recruitingNCT02947685Phase 3Results postedReport a problem
• Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast CancerTerminatedNCT02907918Phase 2Results postedReport a problem
• A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast CancerCompletedNCT02896855Phase 3Results postedReport a problem
• Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain MetastasisTerminatedNCT02774681Phase 2Results postedReport a problem
• Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric CancerTerminatedNCT02726399Phase 2Results postedReport a problem
• Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + DocetaxelCompletedNCT02586025Phase 3Results postedReport a problem
• Brain Irradiation and Tremelimumab in Metastatic Breast CancerCompletedNCT02563925Not applicableResults postedReport a problem
• Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast CancerCompletedNCT02445586Phase 4Results postedReport a problem
• Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain MetastasesCompletedNCT02260531Phase 2Results postedReport a problem
• Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast CancerCompletedNCT02129556Phase 1/2Results postedReport a problem
• Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast CancerCompletedNCT02003209Phase 3Results postedReport a problem
• Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant ChemotherapyCompletedNCT01847001Phase 2Results postedReport a problem
• A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric CancerCompletedNCT01774786Phase 3Results postedReport a problem
• A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast CancerCompletedNCT01432886Phase 1Results postedReport a problem
• Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant ChemotherapyCompletedNCT01401959Phase 2Results postedReport a problem
• Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast CancerCompletedNCT01269346Phase 2Results postedReport a problem
• Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast CancerCompletedNCT01007942Phase 3Results postedReport a problem
• Carboplatin and Bevacizumab for Progressive Breast Cancer Brain MetastasesCompletedNCT01004172Phase 2Results postedReport a problem
• Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab AloneTerminatedNCT00968968Phase 3Results postedReport a problem
• Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast CancerCompletedNCT00876395Phase 3Results postedReport a problem
• Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast CancerCompletedNCT00712881Phase 2Results postedReport a problem
• Trial for Locally Advanced Breast Cancer Using Vorinostat Plus ChemotherapyCompletedNCT00574587Phase 1/2Results postedReport a problem
• Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048)CompletedNCT00550771Phase 2Results postedReport a problem
• Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEUTerminatedNCT00520975Phase 3Results postedReport a problem
• Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction AdenocarcinomaCompletedNCT00515411Phase 2Results postedReport a problem
• A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast CancerCompletedNCT00490646Phase 2Results postedReport a problem
• Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast CancerCompletedNCT00470847Phase 1Results postedReport a problem
• Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast CancerCompletedNCT00464646Phase 2Results postedReport a problem
• Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast CancerCompletedNCT00446030Phase 2Results postedReport a problem
• Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast CancerCompletedNCT00405938Phase 2Results postedReport a problem
• A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.CompletedNCT00391092Phase 3Results postedReport a problem
• Pilot Study of Docetaxel & Bevacizumab +/- Trastuzumab in First-Line Treatment of Patients With Metastatic Breast CancerCompletedNCT00364611Phase 2Results postedReport a problem
• Doxil & Carboplatin Plus HER2+ in Metastatic Breast CancerCompletedNCT00303108Phase 2Results postedReport a problem
• Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast CancerCompletedNCT00201760Phase 2Results postedReport a problem
• A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast CancerCompletedNCT00191451Phase 2Results postedReport a problem
• Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast CancerCompletedNCT00148668Phase 2Results postedReport a problem
• A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast CancerTerminatedNCT00140140Phase 1/2Results postedReport a problem
• XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast CancerCompletedNCT00127933Phase 4Results postedReport a problem
• Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II TrialTerminatedNCT00041470Phase 1/2Results postedReport a problem
• De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast CancerActive, not recruitingNCT07421141Phase 2Report a problem
• Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast CancerCompletedNCT07115095Not applicableReport a problem

← Trastuzumab